Randomized Controlled Double-Blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.

Trial Profile

Randomized Controlled Double-Blind Vs. Placebo Multicentre Study on the Safety and Effectiveness of Thalidomide in the Treatment of Refractory Crohn's Disease and Ulcerative Colitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Dec 2015

At a glance

  • Drugs Thalidomide (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TALIBDP
  • Most Recent Events

    • 16 Feb 2012 Planned End Date changed from 1 Sep 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 16 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 11 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top